Tibsovo® (ivosidenib tablets)
for Myelodysplastic Syndromes
Tibsovo (ivosidenib) is an oral medication targeting the IDH1 mutation, which can cause blood and bone marrow disorders like acute myeloid leukemia (AML). It is used to treat adults with a confirmed IDH1 mutation in newly diagnosed AML (alone or with azacitidine), relapsed or refractory AML, relapsed or refractory myelodysplastic syndromes, and advanced bile duct cancer (cholangiocarcinoma).
